B007
/ Shanghai Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 11
Of
11
Go to page
1
February 11, 2025
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
(clinicaltrials.gov)
- P1 | N=52 | Recruiting | Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd | Trial completion date: Dec 2024 ➔ Dec 2027 | Trial primary completion date: Dec 2024 ➔ Dec 2026
Trial completion date • Trial primary completion date • Glomerulonephritis • Renal Disease
November 29, 2024
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
(clinicaltrials.gov)
- P1 | N=52 | Recruiting | Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd | Trial completion date: Sep 2024 ➔ Dec 2024 | Trial primary completion date: Sep 2024 ➔ Dec 2024
Trial completion date • Trial primary completion date • Glomerulonephritis • Renal Disease
August 06, 2024
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
(clinicaltrials.gov)
- P2/3 | N=216 | Recruiting | Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Glomerulonephritis • Renal Disease
July 22, 2024
A Clinical Study of B007 in the Treatment of Pemphigus.
(clinicaltrials.gov)
- P2/3 | N=132 | Recruiting | Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd | Not yet recruiting ➔ Recruiting
Enrollment open
July 11, 2024
SPH-B007-303: A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.
(clinicaltrials.gov)
- P2/3 | N=104 | Recruiting | Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • CNS Disorders • Myasthenia Gravis
June 24, 2024
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
(clinicaltrials.gov)
- P2/3 | N=216 | Not yet recruiting | Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd
New P2/3 trial • Glomerulonephritis • Renal Disease
June 07, 2024
SPH-B007-303: A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.
(clinicaltrials.gov)
- P2/3 | N=104 | Not yet recruiting | Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd
New P2/3 trial • CNS Disorders • Myasthenia Gravis
June 12, 2024
A Clinical Study of B007 in the Treatment of Pemphigus.
(clinicaltrials.gov)
- P2/3 | N=132 | Not yet recruiting | Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd
New P2/3 trial
May 14, 2024
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
(clinicaltrials.gov)
- P1 | N=52 | Recruiting | Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd | Trial primary completion date: Mar 2024 ➔ Sep 2024
Trial primary completion date • Glomerulonephritis • Renal Disease
March 24, 2023
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
(clinicaltrials.gov)
- P1 | N=52 | Recruiting | Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Glomerulonephritis • Renal Disease
December 29, 2022
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
(clinicaltrials.gov)
- P1 | N=52 | Not yet recruiting | Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd
New P1 trial • Glomerulonephritis • Renal Disease
1 to 11
Of
11
Go to page
1